Search

Your search keyword '"Alland, David"' showing total 585 results
Start Over Author "Alland, David"
585 results on '"Alland, David"'

1. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Author

Georghiou, Sophia B, Rodwell, Timothy C, Korobitsyn, Alexei, Abbadi, Said H, Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C, Chakravorty, Soumitesh, Claxton, Pauline M, Cirillo, Daniela M, Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M, Derendinger, Brigitta, Desmond, Edward P, de Steenwinkel, Jurriaan EM, Dheda, Keertan, Diacon, Andreas H, Dolinger, David L, Dooley, Kelly E, Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R, Fattorini, Lanfranco, Finci, Iris, Le Ray, Laure Fournier, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K, Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L, Kambli, Priti, Kaniga, Koné, Karunaratne, GHR Eranga, Sharma, Meenu Kaushal, Keller, Peter M, Kelly, Ellis C, Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F, Limberis, Jason, Lin, S-Y Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martinez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R, Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P, Merker, Matthias, Miotto, Paolo, Omar, Shaheed V, Otto-Knapp, Ralf, Palaci, Moisés, Gutiérrez, Juan José Palacios, Peacock, Sharon J, Peloquin, Charles A, Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E, Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C, Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R, Spitaleri, Andrea, and Streicher, Elizabeth

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Biodefense, Antimicrobial Resistance, Prevention, Rare Diseases, Emerging Infectious Diseases, Tuberculosis, Clinical Research, Vaccine Related, Orphan Drug, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Infection, Good Health and Well Being, Antitubercular Agents, Drug Resistance, Bacterial, Drug Resistance, Multiple, Bacterial, Humans, Microbial Sensitivity Tests, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Antimycobacterial Susceptibility Testing Group, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology
Abstract

Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance. https://bit.ly/3i43wb6

Published
2022

2. Xpert MTB/RIF Ultra versus mycobacterial growth indicator tube liquid culture for detection of Mycobacterium tuberculosis in symptomatic adults: a diagnostic accuracy study

Author

Xie, Yingda L, Eichberg, Christie, Hapeela, Nchimunya, Nakabugo, Elizabeth, Anyango, Irene, Arora, Kiranjot, Korte, Jeffrey E, Odero, Ronald, van Heerden, Judi, Zemanay, Widaad, Kennedy, Samuel, Nabeta, Pamela, Hanif, Mahmud, Rodrigues, Camilla, Skrahina, Alena, Stevens, Wendy, Dietze, Reynaldo, Liu, Xin, Ellner, Jerrold J, Alland, David, Joloba, Moses L, Schumacher, Samuel G, McCarthy, Kimberly D, Nakiyingi, Lydia, and Dorman, Susan E

Published
2024
Full Text
View/download PDF

3. Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise

Author

Alland, David, Behr, Marcel A, Beko, Busisiwe B, Burhan, Erlina, Churchyard, Gavin, Cobelens, Frank, Denholm, Justin T, Dinkele, Ryan, Ellner, Jerrold J, Fatima, Razia, Haigh, Kate A, Hatherill, Mark, Horton, Katherine C, Kendall, Emily A, Khan, Palwasha Y, MacPherson, Peter, Malherbe, Stephanus T, Mave, Vidya, Mendelsohn, Simon C, Musvosvi, Munyaradzi, Nemes, Elisa, Penn-Nicholson, Adam, Ramamurthy, Dharanidharan, Rangaka, Molebogeng X, Sahu, Suvanand, Schwalb, Alvaro, Shah, Divya K, Sheerin, Dylan, Simon, Donald, Steyn, Adrie J C, Thu Anh, Nguyen, Walzl, Gerhard, Weller, Charlotte L, Williams, Caroline ML, Wong, Emily B, Wood, Robin, Xie, Yingda L, Yi, Siyan, Coussens, Anna K, Zaidi, Syed M A, Allwood, Brian W, Dewan, Puneet K, Gray, Glenda, Kohli, Mikashmi, Kredo, Tamara, Marais, Ben J, Marks, Guy B, Martinez, Leo, Ruhwald, Morten, Scriba, Thomas J, Seddon, James A, Tisile, Phumeza, Warner, Digby F, Wilkinson, Robert J, Esmail, Hanif, and Houben, Rein M G J

Published
2024
Full Text
View/download PDF

5. Author Correction: Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase

Author

Ezewudo, Matthew, Borens, Amanda, Chiner-Oms, Álvaro, Miotto, Paolo, Chindelevitch, Leonid, Starks, Angela M, Hanna, Debra, Liwski, Richard, Zignol, Matteo, Gilpin, Christopher, Niemann, Stefan, Kohl, Thomas Andreas, Warren, Robin M, Crook, Derrick, Gagneux, Sebastien, Hoffner, Sven, Rodrigues, Camilla, Comas, Iñaki, Engelthaler, David M, Alland, David, Rigouts, Leen, Lange, Christoph, Dheda, Keertan, Hasan, Rumina, McNerney, Ruth, Cirillo, Daniela M, Schito, Marco, Rodwell, Timothy C, and Posey, James

Subjects
Microbiology, Biological Sciences, Infection, Good Health and Well Being
Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

7. Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase

Author

Ezewudo, Matthew, Borens, Amanda, Chiner-Oms, Álvaro, Miotto, Paolo, Chindelevitch, Leonid, Starks, Angela M, Hanna, Debra, Liwski, Richard, Zignol, Matteo, Gilpin, Christopher, Niemann, Stefan, Kohl, Thomas Andreas, Warren, Robin M, Crook, Derrick, Gagneux, Sebastien, Hoffner, Sven, Rodrigues, Camilla, Comas, Iñaki, Engelthaler, David M, Alland, David, Rigouts, Leen, Lange, Christoph, Dheda, Keertan, Hasan, Rumina, McNerney, Ruth, Cirillo, Daniela M, Schito, Marco, Rodwell, Timothy C, and Posey, James

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biomedical and Clinical Sciences, Genetics, Microbiology, Clinical Sciences, Human Genome, Tuberculosis, Antimicrobial Resistance, Rare Diseases, Biotechnology, Infectious Diseases, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Antitubercular Agents, Bacterial Proteins, Drug Resistance, Multiple, Bacterial, Genome, Bacterial, Genotype, Humans, Knowledge Bases, Mutation, Mycobacterium tuberculosis, Polymorphism, Single Nucleotide, Sequence Analysis, DNA, Tuberculosis, Multidrug-Resistant, Whole Genome Sequencing
Abstract

Drug-resistant tuberculosis poses a persistent public health threat. The ReSeqTB platform is a collaborative, curated knowledgebase, designed to standardize and aggregate global Mycobacterium tuberculosis complex (MTBC) variant data from whole genome sequencing (WGS) with phenotypic drug susceptibility testing (DST) and clinical data. We developed a unified analysis variant pipeline (UVP) ( https://github.com/CPTR-ReSeqTB/UVP ) to identify variants and assign lineage from MTBC sequence data. Stringent thresholds and quality control measures were incorporated in this open source tool. The pipeline was validated using a well-characterized dataset of 90 diverse MTBC isolates with conventional DST and DNA Sanger sequencing data. The UVP exhibited 98.9% agreement with the variants identified using Sanger sequencing and was 100% concordant with conventional methods of assigning lineage. We analyzed 4636 publicly available MTBC isolates in the ReSeqTB platform representing all seven major MTBC lineages. The variants detected have an above 94% accuracy of predicting drug based on the accompanying DST results in the platform. The aggregation of variants over time in the platform will establish confidence-graded mutations statistically associated with phenotypic drug resistance. These tools serve as critical reference standards for future molecular diagnostic assay developers, researchers, public health agencies and clinicians working towards the control of drug-resistant tuberculosis.

Published
2018

8. RT-PCR negative COVID-19

Author

Parmar, Heta, Montovano, Margaret, Banada, Padmapriya, Pentakota, Sri Ram, Shiau, Stephanie, Ma, Zhongjie, Saibire, Kaheerman, Chopoorian, Abby, O’Shaughnessy, Michael, Hirsch, Mitchell, Jain, Priyanshi, Demirdjian, Gaiane, Karagueuzian, Magali, Robin, Thomas, Salvati, Michael, Patel, Bhavana, Alland, David, and Xie, Yingda L.

Published
2022
Full Text
View/download PDF

13. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis

Author

Miotto, Paolo, Tessema, Belay, Tagliani, Elisa, Chindelevitch, Leonid, Starks, Angela M, Emerson, Claudia, Hanna, Debra, Kim, Peter S, Liwski, Richard, Zignol, Matteo, Gilpin, Christopher, Niemann, Stefan, Denkinger, Claudia M, Fleming, Joy, Warren, Robin M, Crook, Derrick, Posey, James, Gagneux, Sebastien, Hoffner, Sven, Rodrigues, Camilla, Comas, Iñaki, Engelthaler, David M, Murray, Megan, Alland, David, Rigouts, Leen, Lange, Christoph, Dheda, Keertan, Hasan, Rumina, Ranganathan, Uma Devi K, McNerney, Ruth, Ezewudo, Matthew, Cirillo, Daniela M, Schito, Marco, Köser, Claudio U, and Rodwell, Timothy C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Tuberculosis, HIV/AIDS, Antimicrobial Resistance, Genetics, Rare Diseases, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Infection, Good Health and Well Being, Antitubercular Agents, Bacterial Proteins, DNA, Bacterial, Data Interpretation, Statistical, Drug Resistance, Multiple, Bacterial, Genotype, Humans, Microbial Sensitivity Tests, Mutation, Mycobacterium tuberculosis, Phenotype, Sequence Analysis, DNA, Systematic Reviews as Topic, Tuberculosis, Multidrug-Resistant, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology
Abstract

A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium tuberculosis is required to accelerate the development of rapid drug susceptibility testing methods based on genetic sequence.Raw genotype-phenotype correlation data were extracted as part of a comprehensive systematic review to develop a standardised analytical approach for interpreting resistance associated mutations for rifampicin, isoniazid, ofloxacin/levofloxacin, moxifloxacin, amikacin, kanamycin, capreomycin, streptomycin, ethionamide/prothionamide and pyrazinamide. Mutation frequencies in resistant and susceptible isolates were calculated, together with novel statistical measures to classify mutations as high, moderate, minimal or indeterminate confidence for predicting resistance.We identified 286 confidence-graded mutations associated with resistance. Compared to phenotypic methods, sensitivity (95% CI) for rifampicin was 90.3% (89.6-90.9%), while for isoniazid it was 78.2% (77.4-79.0%) and their specificities were 96.3% (95.7-96.8%) and 94.4% (93.1-95.5%), respectively. For second-line drugs, sensitivity varied from 67.4% (64.1-70.6%) for capreomycin to 88.2% (85.1-90.9%) for moxifloxacin, with specificity ranging from 90.0% (87.1-92.5%) for moxifloxacin to 99.5% (99.0-99.8%) for amikacin.This study provides a standardised and comprehensive approach for the interpretation of mutations as predictors of M. tuberculosis drug-resistant phenotypes. These data have implications for the clinical interpretation of molecular diagnostics and next-generation sequencing as well as efficient individualised therapy for patients with drug-resistant tuberculosis.

Published
2017

14. Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data

Author

Barr, David A, Lewis, Joseph M, Feasey, Nicholas, Schutz, Charlotte, Kerkhoff, Andrew D, Jacob, Shevin T, Andrews, Ben, Kelly, Paul, Lakhi, Shabir, Muchemwa, Levy, Bacha, Helio A, Hadad, David J, Bedell, Richard, van Lettow, Monique, Zachariah, Rony, Crump, John A, Alland, David, Corbett, Elizabeth L, Gopinath, Krishnamoorthy, Singh, Sarman, Griesel, Rulan, Maartens, Gary, Mendelson, Marc, Ward, Amy M, Parry, Christopher M, Talbot, Elizabeth A, Munseri, Patricia, Dorman, Susan E, Martinson, Neil, Shah, Maunank, Cain, Kevin, Heilig, Charles M, Varma, Jay K, von Gottberg, Anne, Sacks, Leonard, Wilson, Douglas, Squire, S Bertel, Lalloo, David G, Davies, Gerry, and Meintjes, Graeme

Published
2020
Full Text
View/download PDF

15. A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA

Author

Inoyama, Daigo, Awasthi, Divya, Capodagli, Glenn C., Tsotetsi, Kholiswa, Sukheja, Paridhi, Zimmerman, Matthew, Li, Shao-Gang, Jadhav, Ravindra, Russo, Riccardo, Wang, Xin, Grady, Courtney, Richmann, Todd, Shrestha, Riju, Li, Liping, Ahn, Yong-Mo, Ho Liang, Hsin Pin, Mina, Marizel, Park, Steven, Perlin, David S., Connell, Nancy, Dartois, Véronique, Alland, David, Neiditch, Matthew B., Kumar, Pradeep, and Freundlich, Joel S.

Published
2020
Full Text
View/download PDF

17. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings

Author

Luetkemeyer, Anne F, Firnhaber, Cynthia, Kendall, Michelle A, Wu, Xingye, Mazurek, Gerald H, Benator, Debra A, Arduino, Roberto, Fernandez, Michel, Guy, Elizabeth, Johnson, Pamela, Metchock, Beverly, Sattler, Fred, Telzak, Edward, Wang, Yun F, Weiner, Marc, Swindells, Susan, Sanne, Ian M, Havlir, Diane V, Grinsztejn, Beatriz, and Alland, David

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Lung, Rare Diseases, Prevention, Biodefense, HIV/AIDS, Clinical Research, Vaccine Related, Infectious Diseases, Tuberculosis, Emerging Infectious Diseases, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Infection, Good Health and Well Being, Adult, Antibiotics, Antitubercular, Brazil, DNA, Bacterial, Drug Resistance, Bacterial, Female, Humans, Male, Middle Aged, Mutation, Mycobacterium tuberculosis, Nucleic Acid Amplification Techniques, Prevalence, Rifampin, Sensitivity and Specificity, South Africa, Sputum, Tuberculosis, Pulmonary, United States, Xpert MTB/RIF, tuberculosis diagnosis, respiratory isolation, nontuberculous mycobacteria, HIV/tuberculosis coinfection, AIDS Clinical Trials Group A5295 and Tuberculosis Trials Consortium Study 34 Teams, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundThe Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification test widely used in settings of high tuberculosis prevalence to detect tuberculosis as well asrpoBmutations associated with rifampin resistance. Data are needed on the diagnostic performance of Xpert in lower-prevalence settings to inform appropriate use for both tuberculosis detection and the need for respiratory isolation.MethodsXpert was compared to 2 sputum samples, each evaluated with acid-fast bacilli (AFB) smear and mycobacterial culture using liquid and solid culture media, from participants with suspected pulmonary tuberculosis from the United States, Brazil, and South Africa.ResultsOf 992 participants enrolled with evaluable results, 22% had culture-confirmed tuberculosis. In 638 (64%) US participants, 1 Xpert result demonstrated sensitivity of 85.2% (96.7% in participants with AFB smear-positive [AFB(+)] sputum, 59.3% with AFB smear-negative [AFB(-)] sputum), specificity of 99.2%, negative predictive value (NPV) of 97.6%, and positive predictive value of 94.9%. Results did not differ between higher- and low-prevalence settings. A second Xpert assay increased overall sensitivity to 91.1% (100% if AFB(+), 71.4% if AFB(-)), with specificity of 98.9%. In US participants, a single negative Xpert result predicted the absence of AFB(+)/culture-positive tuberculosis with an NPV of 99.7%; NPV of 2 Xpert assays was 100%, suggesting a role in removing patients from airborne infection isolation. Xpert detected tuberculosis DNA and mutations associated with rifampin resistance in 5 of 7 participants with rifampin-resistant, culture-positive tuberculosis. Specificity for rifampin resistance was 99.5% and NPV was 98.9%.ConclusionsIn the United States, Xpert testing performed comparably to 2 higher-tuberculosis-prevalence settings. These data support the use of Xpert in the initial evaluation of tuberculosis suspects and in algorithms assessing need for respiratory isolation.

Published
2016

21. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study

Author

Dorman, Susan E, Schumacher, Samuel G, Alland, David, Nabeta, Pamela, Armstrong, Derek T, King, Bonnie, Hall, Sandra L, Chakravorty, Soumitesh, Cirillo, Daniela M, Tukvadze, Nestani, Bablishvili, Nino, Stevens, Wendy, Scott, Lesley, Rodrigues, Camilla, Kazi, Mubin I, Joloba, Moses, Nakiyingi, Lydia, Nicol, Mark P, Ghebrekristos, Yonas, Anyango, Irene, Murithi, Wilfred, Dietze, Reynaldo, Peres, Renata Lyrio, Skrahina, Alena, Auchynka, Vera, Chopra, Kamal Kishore, Hanif, Mahmud, Liu, Xin, Yuan, Xing, Boehme, Catharina C, Ellner, Jerrold J, Denkinger, Claudia M, Manabe, Yukari C, Hom, David, Aspindzelashvili, Rusudan, David, Anura, Surve, Utkarsha, Kamulegeya, Louis Henry, Nabweyambo, Sheila, Surtie, Shireen, Hapeela, Nchimunya, Cain, Kevin P, Agaya, Janet, McCarthy, Kimberly D, Marques-Rodrigues, Patricia, Schmidt Castellani, Luiz Guilherme, Almeida, Pedro Sousa, Jr, de Aguiar, Paola Poloni Lobo, Solodovnikova, Varvara, Ruan, Xianglin, Liang, Lili, Zhang, Guolong, Zhu, Hong, Xie, Yingda, and Lyrio Peres, Renata

Published
2018
Full Text
View/download PDF

23. Better Tests, Better Care: Improved Diagnostics for Infectious Diseases

Author

Caliendo, Angela M, Gilbert, David N, Ginocchio, Christine C, Hanson, Kimberly E, May, Larissa, Quinn, Thomas C, Tenover, Fred C, Alland, David, Blaschke, Anne J, Bonomo, Robert A, Carroll, Karen C, Ferraro, Mary Jane, Hirschhorn, Lisa R, Joseph, W Patrick, Karchmer, Tobi, MacIntyre, Ann T, Reller, L Barth, and Jackson, Audrey F

Subjects
Clinical Research, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Communicable Diseases, Health Policy, Health Services Needs and Demand, Humans, Microbiological Techniques, Molecular Diagnostic Techniques, Point-of-Care Systems, Public Health, Infectious Diseases Society of America, clinical microbiology, diagnostics, infectious diseases, molecular diagnostics, point-of-care testing, rapid diagnostics, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

In this IDSA policy paper, we review the current diagnostic landscape, including unmet needs and emerging technologies, and assess the challenges to the development and clinical integration of improved tests. To fulfill the promise of emerging diagnostics, IDSA presents recommendations that address a host of identified barriers. Achieving these goals will require the engagement and coordination of a number of stakeholders, including Congress, funding and regulatory bodies, public health agencies, the diagnostics industry, healthcare systems, professional societies, and individual clinicians.

Published
2013

24. High resolution imaging and five-year tuberculosis contact outcomes

Author

Esmail, Hanif, primary, Coussens, Anna K, additional, Thienemann, Friedrich, additional, Sossen, Bianca, additional, Mukasa, Sandra L, additional, Warwick, James, additional, Goliath, Rene T., additional, Davies, Nashreen Omar, additional, Douglass, Emily, additional, Jackson, Amanda, additional, Lakay, Francisco, additional, Streicher, Elizabeth, additional, Munro, Jacob E., additional, Barrios, Marilou H, additional, Heinsohn, Torben, additional, Macpherson, Liana, additional, Sheerin, Dylan, additional, Aziz, Saalikha, additional, Serole, Keboile, additional, Daroowala, Remy, additional, Taliep, Arshad, additional, Ahlers, Petri, additional, Malherbe, Stephanus T., additional, Bowden, Rory, additional, Warren, Robin, additional, Walzl, Gerhard, additional, Via, Laura E., additional, Bahlo, Melanie, additional, Jacobson, Karen R., additional, Horsburgh, C. Robert, additional, Salgame, Padmini, additional, Alland, David, additional, Barry, Clifton Earl, additional, Flynn, JoAnne L., additional, Ellner, Jerrold J, additional, and Wilkinson, Robert J, additional

Published
2023
Full Text
View/download PDF

25. Host blood RNA signatures predict the outcome of tuberculosis treatment

Author

Du Plessis, Nelita, Loxton, Andre G., Chegou, Novel N., Lee, Myungsun, Thompson, Ethan G., Du, Ying, Malherbe, Stephanus T., Shankar, Smitha, Braun, Jackie, Valvo, Joe, Ronacher, Katharina, Tromp, Gerard, Tabb, David L., Alland, David, Shenai, Shubhada, Via, Laura E., Warwick, James, Aderem, Alan, Scriba, Thomas J., Winter, Jill, Walzl, Gerhard, and Zak, Daniel E.

Published
2017
Full Text
View/download PDF

26. Strains of Mycobacterium tuberculosis transmitting infection in Brazilian households and those associated with community transmission of tuberculosis

Author

Vinhas, Solange Alves, Jones-López, Edward C., Ribeiro Rodrigues, Rodrigo, Gaeddert, Mary, Peres, Renata Lyrio, Marques-Rodrigues, Patricia, de Aguiar, Paola Poloni Lobo, White, Laura Forsberg, Alland, David, Salgame, Padmini, Hom, David, Ellner, Jerrold J., Dietze, Reynaldo, Collins, Lauren F., Shashkina, Elena, Kreiswirth, Barry, and Palaci, Moisés

Published
2017
Full Text
View/download PDF

28. Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response

Author

Malherbe, Stephanus T., Chen, Ray Y., Dupont, Patrick, Kant, Ilse, Kriel, Magdalena, Loxton, André G., Smith, Bronwyn, Beltran, Caroline G. G., van Zyl, Susan, McAnda, Shirely, Abrahams, Charmaine, Maasdorp, Elizna, Doruyter, Alex, Via, Laura E., Barry, III, Clifton E., Alland, David, Richards, Stephanie Griffith-, Ellman, Annare, Peppard, Thomas, Belisle, John, Tromp, Gerard, Ronacher, Katharina, Warwick, James M., Winter, Jill, and Walzl, Gerhard

Published
2020
Full Text
View/download PDF

31. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings

Author

AIDS Clinical Trials Group A5295 and Tuberculosis Trials Consortium Study 34 Teams, Luetkemeyer, Anne F., Firnhaber, Cynthia, Kendall, Michelle A., Wu, Xingye, Mazurek, Gerald H., Benator, Debra A., Arduino, Roberto, Fernandez, Michel, Guy, Elizabeth, Johnson, Pamela, Metchock, Beverly, Sattler, Fred, Telzak, Edward, Wang, Yun F., Weiner, Marc, Swindells, Susan, Sanne, Ian M., Havlir, Diane V., Grinsztejn, Beatriz, and Alland, David

Published
2016

32. Persistence of SARS-CoV-2 in saliva: Implications for late-stage diagnosis and infectious duration

Author

Chopoorian, Abby, primary, Banada, Padmapriya, additional, Reiss, Robert, additional, Elson, David, additional, Desind, Samuel, additional, Park, Claire, additional, Banik, Sukalyani, additional, Hennig, Emily, additional, Wats, Aanchal, additional, Togba, Austin, additional, Wei, Abraham, additional, Daivaa, Naranjargal, additional, Palo, Laura, additional, Hirsch, Mitchell, additional, Campbell, Carter, additional, Saiganesh, Pooja, additional, Alland, David, additional, and Xie, Yingda L., additional

Published
2023
Full Text
View/download PDF

33. Diagnostic Accuracy of the NOVA Tuberculosis Total Antibody Rapid Test for Detection of Pulmonary Tuberculosis and Infection with Mycobacterium Tuberculosis

Author

Nsubuga, Gideon, primary, Kennedy, Samuel, additional, Rani, Yashi, additional, Hafiz, Zibran, additional, Kim, Soyeon, additional, Ruhwald, Morten, additional, Alland, David, additional, Ellner, Jerrold J., additional, Joloba, Moses, additional, Dorman, Susan E., additional, Penn-Nicholson, Adam, additional, and Nakiyingi, Lydia, additional

Published
2023
Full Text
View/download PDF

37. Serologic Responses in Childhood Pulmonary Tuberculosis

Author

Nonyane, Bareng A. S., Nicol, Mark P., Andreas, Nicholas J., Rimmele, Stefanie, Schneiderhan-Marra, Nicole, Workman, Lesley J., Perkins, Mark D., Joos, Thomas, Broger, Tobias, Ellner, Jerrold J., Alland, David, Kampmann, Beate, Dorman, Susan E., and Zar, Heather J.

Published
2018
Full Text
View/download PDF

38. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure

Author

Malherbe, Stephanus T, Shenai, Shubhada, Ronacher, Katharina, Loxton, Andre G, Dolganov, Gregory, Kriel, Magdalena, Van, Tran, Chen, Ray Y, Warwick, James, Via, Laura E, Song, Taeksun, Lee, Myungsun, Schoolnik, Gary, Tromp, Gerard, Alland, David, Barry, Clifton E, III, Winter, Jill, Walzl, Gerhard, Lucas, Lance, Spuy, Gian van der, Stanley, Kim, Theart, Lani, Smith, Bronwyn, Du Plessis, Nelita, Beltran, Caroline G G, Maasdorp, Elizna, Ellmann, Annare, Choi, Hongjo, Joh, Joonsung, Dodd, Lori E, Allwood, Brian, Kogelenberg, Coenie, Vorster, Morné, and Griffith-Richards, Stephanie

Subjects
Positron emission tomography -- Usage -- Analysis, Tuberculosis -- Research, Messenger RNA -- Research, Mycobacterium tuberculosis -- Care and treatment, Biological sciences, Health
Abstract

The absence of a gold standard to determine when antibiotics induce a sterilizing cure has confounded the development of new approaches to treat pulmonary tuberculosis (PTB). We detected positron emission tomography and computerized tomography (PET-CT) imaging response patterns consistent with active disease, along with the presence of Mycobacterium tuberculosis (MTB) mRNA in sputum and bronchoalveolar lavage samples, in a substantial proportion of adult, HIV-negative patients with PTB after a standard 6-month treatment plus 1 year follow-up, including patients with a durable cure and others who later developed recurrent disease. The presence of MTB mRNA in the context of nonresolving and intensifying lesions on PET-CT images might indicate ongoing transcription, suggesting that even apparently curative treatment for PTB may not eradicate all of the MTB bacteria in most patients. This suggests an important complementary role for the immune response in maintaining a disease-free state. Sterilizing drugs or host-directed therapies, and better treatment response markers, are probably needed for the successful development of improved and shortened PTB-treatment strategies., Author(s): Stephanus T Malherbe (corresponding author) [1, 2]; Shubhada Shenai [3]; Katharina Ronacher [1, 2]; Andre G Loxton [1, 2]; Gregory Dolganov [4]; Magdalena Kriel [1, 2]; Tran Van [4]; [...]

Published
2016
Full Text
View/download PDF

39. A comprehensive update to the Mycobacterium tuberculosis H37Rv reference genome

Author

Chitale, Poonam, primary, Lemenze, Alexander D., additional, Fogarty, Emily C., additional, Shah, Avi, additional, Grady, Courtney, additional, Odom-Mabey, Aubrey R., additional, Johnson, W. Evan, additional, Yang, Jason H., additional, Eren, A. Murat, additional, Brosch, Roland, additional, Kumar, Pradeep, additional, and Alland, David, additional

Published
2022
Full Text
View/download PDF

40. Development of amidase-dependent pyrazinoic acid prodrugs with activity against pyrazinamide resistant Mycobacterium tuberculosis

Author

Levine, Carly, primary, Jadhav, Ravindra, additional, Pan, Yan, additional, Tsotetsi, Kholiswa, additional, Wang, Xin, additional, Awasthi, Divya, additional, Grady, Courtney, additional, Shelke, Anil, additional, Daher, Samer S., additional, Richmann, Todd, additional, Shrestha, Riju, additional, Sukheja, Paridhi, additional, Patel, Jimmy, additional, Barnett, Pamela R., additional, Dikdan, Ryan J., additional, Kim, Thomas, additional, Russo, Riccardo, additional, Hanna, Jennifer, additional, Zimmerman, Matthew, additional, Dartois, Véronique, additional, Freundlich, Joel S., additional, Alland, David, additional, and Kumar, Pradeep, additional

Published
2022
Full Text
View/download PDF

41. Better Tests, Better Care: Improved Diagnostics for Infectious Diseases

Author

Infectious Diseases Society of America (IDSA), Caliendo, Angela M., Gilbert, David N., Ginocchio, Christine C., Hanson, Kimberly E., May, Larissa, Quinn, Thomas C., Tenover, Fred C., Alland, David, Blaschke, Anne J., Bonomo, Robert A., Carroll, Karen C., Ferraro, Mary Jane, Hirschhorn, Lisa R., Joseph, W. Patrick, Karchmer, Tobi, MacIntyre, Ann T., Reller, L. Barth, and Jackson, Audrey F.

Published
2013
Full Text
View/download PDF

42. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Author

Ministerio de Ciencia e Innovación (España), European Research Council, Comas, Iñaki [0000-0001-5504-9408], Antimycobacterial Susceptibility Testing Group, Georghiou, Sophia B., Rodwell, Timothy C., Korobitsyn, Alexei, Abbadi, Said H., Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C., Chakravorty, Soumitesh, Claxton, Pauline M., Cirillo, Daniela M., Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M., Derendinger, Brigitta, Desmond, Edward P., Steenwinkel, Jurriaan E. M. de, Dheda, Keertan, Diacon, Andreas H., Dolinger, David L., Dooley, Kelly E., Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R., Fattorini, Lanfranco, Finci, Iris, Fournier Le Ray, Laure, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K., Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L., Kambli, Priti, Kaniga, Koné, Karunaratne, G. H. R. Eranga, Sharma, Meenu Kaushal, Keller, Peter M., Kelly, Ellis C., Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F., Limberis, Jason, Lin, S-Y. Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martínez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R., Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P., Merker, Matthias, Miotto, Paolo, Omar, Shaheed V., Otto-Knapp, Ralf, Palaci, Moisés, Palacios Gutiérrez, Juan José, Peacock, Sharon J., Peloquin, Charles A., Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E., Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C., Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R., Spitaleri, Andrea, Streicher, Elizabeth, Supply, Philip, Svensson, Erik, Tagliani, Elisa, Tahseen, Sabira, Takaki, Akiko, Theron, Grant, Torrea, Gabriela, Van Deun, Armand, van Ingen, Jakko, Van Rie, Annelies, van Soolingen, Dick, Vargas Jr, Roger, Venter, Amour, Veziris, Nicolas, Villellas, Cristina, Viveiros, Miguel, Warren, Robin, Wen, Shu'an, Werngren, Jim, Wilkinson, Robert J., Yang, Caie, Yılmaz, F. Ferda, Zhang, Tingting, Zimenkov, Danila, Ismail, Nazir, Köser, Claudio U., Schön, Thomas, Ministerio de Ciencia e Innovación (España), European Research Council, Comas, Iñaki [0000-0001-5504-9408], Antimycobacterial Susceptibility Testing Group, Georghiou, Sophia B., Rodwell, Timothy C., Korobitsyn, Alexei, Abbadi, Said H., Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C., Chakravorty, Soumitesh, Claxton, Pauline M., Cirillo, Daniela M., Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M., Derendinger, Brigitta, Desmond, Edward P., Steenwinkel, Jurriaan E. M. de, Dheda, Keertan, Diacon, Andreas H., Dolinger, David L., Dooley, Kelly E., Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R., Fattorini, Lanfranco, Finci, Iris, Fournier Le Ray, Laure, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K., Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L., Kambli, Priti, Kaniga, Koné, Karunaratne, G. H. R. Eranga, Sharma, Meenu Kaushal, Keller, Peter M., Kelly, Ellis C., Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F., Limberis, Jason, Lin, S-Y. Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martínez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R., Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P., Merker, Matthias, Miotto, Paolo, Omar, Shaheed V., Otto-Knapp, Ralf, Palaci, Moisés, Palacios Gutiérrez, Juan José, Peacock, Sharon J., Peloquin, Charles A., Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E., Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C., Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R., Spitaleri, Andrea, Streicher, Elizabeth, Supply, Philip, Svensson, Erik, Tagliani, Elisa, Tahseen, Sabira, Takaki, Akiko, Theron, Grant, Torrea, Gabriela, Van Deun, Armand, van Ingen, Jakko, Van Rie, Annelies, van Soolingen, Dick, Vargas Jr, Roger, Venter, Amour, Veziris, Nicolas, Villellas, Cristina, Viveiros, Miguel, Warren, Robin, Wen, Shu'an, Werngren, Jim, Wilkinson, Robert J., Yang, Caie, Yılmaz, F. Ferda, Zhang, Tingting, Zimenkov, Danila, Ismail, Nazir, Köser, Claudio U., and Schön, Thomas

Abstract

Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance.

Published
2022

43. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis

Author

Xie, Yingda L., Chakravorty, Soumitesh, Armstrong, Derek T., Hall, Sandra L., Via, Laura E., Song, Taeksun, Yuan, Xing, Mo, Xiaoying, Zhu, Hong, Xu, Peng, Gao, Qian, Lee, Myungsun, Lee, Jongseok, Smith, Laura E., Chen, Ray Y., Joh, Joon Sung, Cho, YoungSoo, Liu, Xin, Ruan, Xianglin, Liang, Lili, Dharan, Nila, Cho, Sang-Nae, Barry, Clifton E., III, Ellner, Jerrold J., Dorman, Susan E., and Alland, David

Published
2017
Full Text
View/download PDF

44. Clinical Research and Development of Tuberculosis Diagnostics: Moving From Silos to Synergy

Author

Nahid, Payam, Kim, Peter S., Evans, Carlton A., Alland, David, Barer, Michael, Diefenbach, Jane, Ellner, Jerrold, Hafner, Richard, Hamilton, Carol Dukes, Iademarco, Michael F., Ireton, Gregory, Kimerling, Michael E., Lienhardt, Christian, MacKenzie, William R., Murray, Megan, Perkins, Mark D., Posey, Jamie E., Roberts, Teri, Sizemore, Christine, Stevens, Wendy S., Via, Laura, Williams, Sharon D., Yew, Wing W., and Swindells, Susan

Published
2012
Full Text
View/download PDF

45. Development of a Novel Human CD147 Knock-in NSG Mouse Model to Test SARS-CoV-2 Viral Infection

Author

Badeti, Saiaditya, primary, Jiang, Qingkui, additional, Naghizadeh, Alireza, additional, Tseng, Hsiang-chi, additional, Bushkin, Yuri, additional, Marras, Salvatore A.E., additional, Nisa, Annuurun, additional, Tyagi, Sanjay, additional, Chen, Fei, additional, Romanienko, Peter, additional, Yehia, Ghassan, additional, Evans, Deborah, additional, Lopez-Gonzalez, Moises, additional, Alland, David, additional, Russo, Riccardo, additional, Gause, William, additional, Shi, Lanbo, additional, and Liu, Dongfang, additional

Published
2022
Full Text
View/download PDF

46. Additional file 1 of Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection

Author

Badeti, Saiaditya, Jiang, Qingkui, Naghizadeh, Alireza, Tseng, Hsiang-chi, Bushkin, Yuri, Marras, Salvatore A. E., Nisa, Annuurun, Tyagi, Sanjay, Chen, Fei, Romanienko, Peter, Yehia, Ghassan, Evans, Deborah, Lopez-Gonzalez, Moises, Alland, David, Russo, Riccardo, Gause, William, Shi, Lanbo, and Liu, Dongfang

Abstract

Additional file 1: Figure S1. Similar distribution of transgenic hCD147 protein by immunohistochemistry in various tissues in hCD147KIhet-NSG mice relative to WT-NSG mice. Tissues from wild-type NSG mice (left) were stained for mouse CD147 protein using rabbit anti-mouse primary antibody (R&D Systems, BAF772; 1:100) and tissues from hCD147KIhet-NSG mice (right) were stained for human CD147 protein using mouse anti-human primary antibody (HIM6; 1:500). Images were taken using an Olympus Inverted Light Microscope. Scale bar represents 100 µm. Figure S2. Specificity of anti-human CD147 and anti-mouse CD147 antibodies tested against human and mouse cell lines. Representative contour plots of CD147 expression on BNL 1ME A.7R.1 (top) and HepG2 (bottom) cells using antibodies targeting either mouse CD147 protein, human CD147 protein, or a combination of both antibodies (far right). Relative percentages are listed, and significant shifts highlighted in red. Gating was determined based on donkey anti-goat and mouse isotype IgG antibody background staining. Figure S3. Reduction of body weight 2 days post-infection in SARS-CoV-2 infected hACE2KI-NSG and K18-hACE2-B6 mice, and slight body weight reduction in infected hCD147KI-NSG mice. Average body weight loss as a percent of original body weight in WT-NSG (n=3), hCD147KI-NSG (n=3), hACE2KI-NSG (n=4), and K18-hACE2-B6 (n=3) mice following intranasal infection with the TCID50 dose of SARS-CoV-2 virus (1×105 PFU in 25ul per nostril). Error bars represent standard error measure (SEM). Statistical significance was determined using an unpaired one-tailed Student t test. *indicates significance of p

Published
2022
Full Text
View/download PDF

47. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Author

Antimycobacterial Susceptibility Testing Group, Georghiou, Sophia B., Rodwell, Timothy C., Korobitsyn, Alexei, Abbadi, Said H., Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C., Chakravorty, Soumitesh, Claxton, Pauline M., Cirillo, Daniela M., Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M., Derendinger, Brigitta, Desmond, Edward P., Steenwinkel, Jurriaan E. M. de, Dheda, Keertan, Diacon, Andreas H., Dolinger, David L., Dooley, Kelly E., Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R., Fattorini, Lanfranco, Finci, Iris, Fournier Le Ray, Laure, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K., Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L., Kambli, Priti, Kaniga, Koné, Karunaratne, G. H. R. Eranga, Sharma, Meenu Kaushal, Keller, Peter M., Kelly, Ellis C., Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F., Limberis, Jason, Lin, S-Y. Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martínez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R., Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P., Merker, Matthias, Miotto, Paolo, Omar, Shaheed V., Otto-Knapp, Ralf, Palaci, Moisés, Palacios Gutiérrez, Juan José, Peacock, Sharon J., Peloquin, Charles A., Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E., Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C., Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R., Spitaleri, Andrea, Streicher, Elizabeth, Supply, Philip, Svensson, Erik, Tagliani, Elisa, Tahseen, Sabira, Takaki, Akiko, Theron, Grant, Torrea, Gabriela, Van Deun, Armand, van Ingen, Jakko, Van Rie, Annelies, van Soolingen, Dick, Vargas Jr, Roger, Venter, Amour, Veziris, Nicolas, Villellas, Cristina, Viveiros, Miguel, Warren, Robin, Wen, Shu'an, Werngren, Jim, Wilkinson, Robert J., Yang, Caie, Yılmaz, F. Ferda, Zhang, Tingting, Zimenkov, Danila, Ismail, Nazir, Köser, Claudio U., Schön, Thomas, University of Zurich, Antimycobacterial Susceptibility Testing Group, Department of Genetics [Cambridge], University of Cambridge [UK] (CAM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Institut de médecine et d'épidémiologie appliquée [AP-HP Hôpital Bichat-Claude Bernard] (IMEA), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), As current or former employees or consultants for FIND, the work of R.B. Baldan, I. Comas, C.M. Denkinger, D.L. Dolinger, S.B. Georghiou, C.U. Köser and T.C. Rodwell on the systematic reviews, including this viewpoint, was supported by Unitaid (grant 2019-32-FIND MDR), BMGF (grant OPP1105925), the German Federal Ministry of Education and Research through KfW, the Dutch Ministry of Foreign Affairs, the Australian Department of Foreign Affairs and Trade, and UK aid from the British people. N. Alvarez and J. Robledo are funded by MinCiencias, Colombia (number 221389666216 CT-783-2018). A. Aubry and N. Veziris work at the Centre National de Reference des Mycobactéries, which receives an annual grant from Santé Publique France and have received research grants from Janssen for studies on bedaquiline. P. Claxton and I.F. Laurenson are funded through National Services Scotland. I. Comas was supported by PID2019-104477RB-I00 from the Spanish Science Ministry and by ERC (CoG 101001038). M. Egger is supported by the Swiss National Science Foundation (grant number 320030_153442 and 189498) and the US National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific, U01AI069907, CCASAnet, U01AI069923, Central Africa, U01AI096299, East Africa, U01AI069911, NA-ACCORD, U01AI069918, Southern Africa, U01AI069924, West Africa, U01AI069919. M.R. Farhat is supported by NIH NIAID R01AI155765. S.K. Heysell was funded by NIH NIAID grants R01 AI137080 and U01 AI150508. T. Jagielski was supported by a DAINA grant (number 2017/27/L/NZ6/03279) from the National Science Centre, Poland. J.L. Johnson was supported by contracts NO1-AI95383 and NO1-AI-70022 of the US National Institutes of Health. P.M. Keller was supported by Innosuisse 36198.1 IP-LS. C.U. Köser is a research associate at Wolfson College and visiting scientist at the Department of Genetics, University of Cambridge. The Federal Government of Germany supported C.U. Köser as part of his work for the European Laboratory Initiative, WHO Regional Office for Europe. C.U. Köser was further supported by the Royal Society of Tropical Medicine and Hygiene and the National Institute for Health Research Cambridge Biomedical Research Centre and received an observership by the European Society of Clinical Microbiology and Infectious Diseases to the EUCAST Development Laboratory for Bacteria (Växjö, Sweden), hosted by Gunnar Kahlmeter and Erika Matuschek. D. Machado and M. Viveiros are funded in part by Fundação para a Ciência e a Tecnologia, Portugal (PTDC/BIA-MIC/30692/2017, UID/Multi/04413/2020 and DL57/ CEECIND/0256/2017). S. Niemann is supported by the German Center for Infection Research, Excellenz Cluster Precision Medicine in Chronic Inflammation EXC 2167, Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG). S.V. Omar has received funding to prepare and provide training for Janssen Pharmaceutica activities. L. Rigouts is supported by the Belgian Directorate General for Development. T.C. Rodwell was additionally funded in part by FIND and NIH NIAD, grants: P30 AI036214 and R21 AI135756. T. Schön is funded by the Swedish Heart and Lung Foundation and the Swedish Research Council. T.R. Sterling has received funding from the US National Institutes of Health and the Centers for Disease Control and Prevention. G. Theron and R. Warren are supported by baseline funding from the South African Medical Research Council. R.J. Wilkinson receives funding from the Wellcome Trust (203135) and from the Francis Crick Institute, which is supported by Cancer Research UK (FC0010218), UKRI (FC0010218) and the Wellcome Trust (FC0010218), Ministerio de Ciencia e Innovación (España), European Research Council, Comas, Iñaki, Comas, Iñaki [0000-0001-5504-9408], Antimycobacterial Susceptibility T, and Wellcome Trust

Subjects
[SDV]Life Sciences [q-bio], Respiratory System, Drug Resistance, Antitubercular Agents, Infektionsmedicin, Medical and Health Sciences, Drug Resistance, Multiple, Bacterial, Tuberculosis, Multidrug-Resistant, 11 Medical and Health Sciences, Human Biology & Physiology, MESH: Microbial Sensitivity Tests, 10179 Institute of Medical Microbiology, Bacterial, Multidrug-Resistant, Infectious Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Infection, Life Sciences & Biomedicine, Multiple, Model organisms, Pulmonary and Respiratory Medicine, Infectious Medicine, Immunology, Infectious Disease, 610 Medicine & health, Microbial Sensitivity Tests, Vaccine Related, Rare Diseases, Clinical Research, Biodefense, MESH: Drug Resistance, Bacterial, Drug Resistance, Bacterial, Tuberculosis, Humans, Science & Technology, MESH: Humans, Antimycobacterial Susceptibility Testing Group, FOS: Clinical medicine, Prevention, MESH: Drug Resistance, Multiple, Bacterial, Mycobacterium tuberculosis, Eucast, MESH: Antitubercular Agents, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Orphan Drug, Emerging Infectious Diseases, Good Health and Well Being, 2740 Pulmonary and Respiratory Medicine, 570 Life sciences, biology, Human medicine, Antimicrobial Resistance, Model
Abstract

11 páginas, 2 figuras, 1 tabla, Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance., I. Comas was supported by PID2019-104477RB-I00 from the Spanish Science Ministry and by ERC (CoG 101001038)

Published
2022
Full Text
View/download PDF

50. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study

Author

Boehme, Catharina C, Nicol, Mark P, Nabeta, Pamela, Michael, Joy S, Gotuzzo, Eduardo, Tahirli, Rasim, Gler, Ma Tarcela, Blakemore, Robert, Worodria, William, Gray, Christen, Huang, Laurence, Caceres, Tatiana, Mehdiyev, Rafail, Raymond, Lawrence, Whitelaw, Andrew, Sagadevan, Kalaiselvan, Alexander, Heather, Albert, Heidi, Cobelens, Frank, Cox, Helen, Alland, David, and Perkins, Mark D

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results